Isoflavone derivatives

US6958156B2 · kind B2 · utility

Assignee

• Vyrex Corporation · US

Inventors

• Sheldon S. Hendler · Village of La Jolla, US
• Jan Zielinski · San Diego, US

Key dates

• Filing date: Feb 20, 2003
• Grant date: Oct 25, 2005
• Expiry date: Mar 22, 2024

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2800/522
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Isoflavones are modified by esterification at one or more of the C4′, C5, C6, and C7 positions to promote bioavailability, and especially to enhance solubility over the corresponding unesterified isoflavones. Preferred modifications produce a carboxylic acid hemiester or a phosphate ester which is biologically hydrolysable. Preferred starting isoflavones are genistin and daidzin, and still more preferably comprises an aglycone form such as genistein or daidzein. Esterified isoflavones may be employed therapeutically or prophylactically for a variety of conditions, provided as a dietary supplement, or added to natural or processed food-stuffs. Further preferred uses include incorporation of contemplated compounds into topical formulations, and especially cosmetic topical formulations.